Aptose Biosciences (APS) AI Stock Analysis

• Market Cap: C$6.18M
• Dividend Yield: N/A
• Average Volume (3M): 3.93K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.37
• Revenue Growth: N/A
• EPS Growth: 79.63%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -3.64
• Shares Outstanding: 2,552,429
• 10 Day Avg. Volume: 1,012
• 30 Day Avg. Volume: 3,931
• PEG Ratio: 0.20
• Price to Book (P/B): 21.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.62
• Enterprise Value/Market Cap: 123.15
• Enterprise Value/Revenue: 398.16
• Enterprise Value/Gross Profit: -6.45K
• Enterprise Value/Ebitda: -6.22
• 1Y Price Target: C$8.20
• Price Target Upside: 244.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 37 Underperform
• Price Target: ―

Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock's weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.

Positive Factors

Clinical Trials

The TUSCANY trial could position TUS as a promising combination therapy for larger AML populations, avoiding the toxicities observed with other agents.

Efficacy

Two FLT3-WT patients achieved complete remissions by the end of Cycle 1, with a patient having biallelic TP53 mutations and a complex karyotype achieving a complete remission.

Financial Strategy

Aptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Negative Factors

Financial Position

The company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Aptose Biosciences Business Overview & Revenue Model

Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

How the Company Makes Money

Aptose Biosciences generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company seeks to monetize its innovations through strategic partnerships with larger pharmaceutical companies, licensing agreements, and eventual sales of approved therapeutics. Revenue streams may include upfront payments, milestone payments, royalties on product sales, and research and development funding from partners. As a clinical-stage company, Aptose's financial performance heavily depends on the successful clinical development, regulatory approval, and commercialization of its drug candidates.

Aptose Biosciences Financial Statement Overview

Summary

Aptose Biosciences exhibits significant financial challenges with no revenue and substantial losses. The company's negative equity and high liabilities further emphasize its financial instability. Cash flow is negative, indicating cash burn, although financing activities provide temporary liquidity.

Income Statement

Aptose Biosciences has consistently reported zero revenue over the analyzed periods, with significant negative EBIT and net income, indicating high operational losses. The lack of revenue growth and persistent negative profit margins suggest substantial challenges in generating income and controlling expenses.

Balance Sheet

The company's balance sheet shows negative stockholders' equity and high liabilities relative to assets, signaling financial instability and high leverage. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities pose a risk. The negative equity ratio further highlights the company's financial distress.

Cash Flow

Aptose Biosciences exhibits negative operating and free cash flows, reflecting cash burn without revenue generation. The free cash flow to net income ratio is unfavorable due to negative values, and the operating cash flow further indicates cash inefficiency, though financing activities provide temporary liquidity support.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-117.97K	0.00	-474.55K	-507.08K	-616.53K	-646.43K
	EBIT
-21.96M	0.00	-52.36M	-42.60M	-65.45M	-55.77M
	EBITDA
-20.71M	0.00	-52.27M	-42.48M	-65.30M	-55.62M
	Net Income Common Stockholders
-21.33M	-25.43M	-51.21M	-41.82M	-65.35M	-55.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.70M	6.15M	9.25M	46.96M	79.13M	122.39M
	Total Assets
7.47M	10.13M	12.99M	51.03M	82.53M	126.26M
	Total Debt
8.98M	621.00K	1.01M	1.30M	574.00K	1.07M
	Net Debt
4.28M	-5.53M	-8.24M	-35.67M	-38.54M	-116.32M
	Total Liabilities
14.86M	14.67M	15.89M	13.29M	8.29M	7.35M
	Stockholders Equity
-7.39M	-4.54M	-2.90M	37.74M	74.24M	118.92M
Cash Flow		Free Cash Flow
-27.01M	-35.98M	-44.62M	-32.35M	-43.52M	-33.97M
	Operating Cash Flow
-27.01M	-35.98M	-44.59M	-32.32M	-43.30M	-33.89M
	Investing Cash Flow
2.01M	18.00K	9.96M	30.07M	-35.21M	12.63M
	Financing Cash Flow
22.40M	33.41M	6.91M	116.00K	226.00K	58.81M

Aptose Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APS, the sentiment is Negative. The current price of 2.38 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.72, and below the 200-day MA of 8.80, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 42.90 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APS.

Aptose Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
APS	37 Underperform	C$6.18M	―	391.94%	―	―	79.63%
XRTX	36 Underperform	C$4.55M	―	-38.24%	―	―	-22.96%
BIOV	29 Underperform	$10.20M	―		―	―	48.63%

Aptose Biosciences Corporate Events

Aptose Biosciences Advances AML Therapy and Strengthens Financial Position

Aptose Biosciences has reported its year-end 2024 results and highlighted significant advancements in its tuspetinib-based triple drug therapy for AML. The ongoing TUSCANY clinical trial has shown promising results, achieving complete remissions in difficult-to-treat AML patients. The company has also signed a debt conversion agreement with Hanmi Pharmaceutical and entered a cooperative research agreement with the National Cancer Institute to further develop tuspetinib. These developments are expected to enhance Aptose’s position in the oncology market and provide additional funding for its clinical programs.

Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment

Aptose Biosciences has reported promising early results from their TUSCANY trial, involving the TUS+VEN+AZA triplet therapy for newly diagnosed AML patients. The trial, which uses a combination of tuspetinib, venetoclax, and azacitidine, has shown complete remissions in patients with TP53-mutated and FLT3-wildtype AML, demonstrating favorable safety and efficacy. These results indicate a potential new frontline treatment for a diverse group of AML patients, enhancing Aptose’s position in the oncology field and offering hope for stakeholders.